HETEROCYCLES, Vol. 94, No. 12, 2017, pp. 2307 - 2316. © 2017 The Japan Institute of Heterocyclic Chemistry
Received, 13th October, 2017, Accepted, 10th November, 2017, Published online, 15th November, 2017
DOI: 10.3987/COM-17-13823

SYNTHESIS OF 3-(ALKYLSULFANYL)-1,4-BENZOTHIAZINE DERIVATIVES BASED ON CYCLIZATION OF 2-[(CYANOMETHYL)SULFANYL]PHENYL ISOTHIOCYANATE

Kazuhiro Kobayashi,* Hiroki Inouchi, Ryo Hasegawa, and Kazuki Kawano

Applied Chemistry Field, Chemistry and Biotechnology Course, Department of Engineering, Graduate School of Sustainability Science, Tottori University, 4-101 Koyama-minami, Tottori 680-8552, Japan. E-mail: kkoba@chem.tottori-u.ac.jp

Abstract – Efficient procedures for the preparation of 1,4-benzothiazine-based bicyclic and tricyclic heterocycles have been developed. The reaction of 2-[(cyanomethyl)sulfanyl]phenyl isothiocyanate, readily prepared from commercially available 2-aminobenzenethiol, with sodium hydride was found to give, after aqueous workup, 3-thioxo-3,4-dihydro-2*H*-1,4-benzothiazine-2-carbonitrile. Treatment with alkyl halides prior to workup yielded 3-(alkylsulfanyl)-4*H*-1,4-benzothiazine-2-carbonitriles. Successive treatment of these compounds with sodium hydride and alkyl halides afforded 4-alkyl-3-(alkylsulfanyl)-2*H*-1,4-benzothiazine-2-carbonitriles. These procedures can be applied to the synthesis of some 1,4-benzothiazine-based tricyclic heterocycles.

A number of 4*H*-1,4-benzothiazine derivatives have recently been synthesized and some of these compounds have been reported to exhibit biological activities.[1] 2*H*-1,4-Benzothiazine derivatives have also attracted respectable attention in recent years due to their potential use as biologically active compounds.[2] Some 2*H*-[3] and 4*H*-1,4-benzothiazine[4] derivatives have been used for the preparation of more structurally complex organic compounds. The literature procedures to prepare 2*H*-1,4-benzothiazines usually involve the reactions of 2-aminobenzenethiol with α-halo ketones,[5] though a few new syntheses of 2*H*-1,4-benzothiazine derivative have recently been reported.[6] However, there have been no methods, which can allow preparation of 2*H*- or 4*H*-1,4-benzothiazine derivatives carrying an alkylsulfanyl group at the 3-position, while a few method for the preparation of 3,4-dihydro-2*H*-1,4-benzothiazine-3-thiones have been reported.[7] In this manuscript, we wish to report a convenient and direct method for the preparation of 2-(alkylsulfanyl)-4*H*-1,4-benzothiazine (**4**) and 2-(alkylsulfanyl)-2*H*-

1,4-benzothiazine derivatives (**5**) and (**6**) from 2-[(cyanomethyl)sulfanyl]phenyl isothiocyanate (**2**).

The starting isothiocyanate (**2**) was prepared in a good yield by the treatment of 2-[(cyanomethyl)sulfanyl]phenyl isocyanide (**1**),[8] easily accessible from commercially available 2-aminobenzenethiol, with sulfur in the presence of triethylamine and a catalytic amount of selenium[9] as shown in Scheme 1. First, compound (**2**) was allowed to react with sodium hydride in DMF at 0 ˚C. After aqueous workup, 3-thioxo-3,4-dihydro-2*H*-1,4-benzothiazine-2-carbonitrile (**3**) was obtained in an excellent yield as shown in Scheme 1 as well. Addition of haloalkanes prior to aqueous workup resulted in the formation of 3-(alkylsulfanyl)-4*H*-1,4-benzothiazine-2-carbonitriles (**4**), as shown in Scheme 2. We have prepared a range of these derivatives using this methodology and the results are compiled in Table 1, which indicates that not only reactive haloalkanes but also a normal haloalkane, such as *n*-butyl bromide can be used, though the yields of the products **4b** is somewhat lower (Entry 2) than the others.



1 **2** 85% **3** 90%

Scheme 1



2 **4**

Scheme 2

Table 1. Preparation of 2-(alkylsulfanyl)-4*H*-1,4-benzothiazines (**4**)

Entry	RX	**4**	Yield/%[a]
1	MeI	**4a**	68
2	*n*-BuBr	**4b**	47
3	CH_2=$CHCH_2Br$	**4c**	78
4	BnBr	**4d**	86
5	$PhCOCH_2Br$	**4e**	80
6	4-$ClC_6H_4COCH_2Br$	**4f**	80
7	*t*-$BuOCOCH_2Br$	**4g**	68
8	$NCCH_2Br$	**4h**	62

[a] Yields of isolated products.

The deprotonation of some of compounds (**4**) with sodium hydride in DMF at 0 ˚C followed by treatment with haloalkanes afforded 2-alkyl-3-(alkylsulfanyl)-2*H*-1,4-benzothiazines (**5**) in fair yields, as depicted

in Scheme 3. The 2*H*-1,4-benzothiazine structure was determined by their IR and NMR spectral data. The IR spectra uniformly exhibit very weak bands due to nitrile triple bonds around 2230 cm^{-1}. Signals around δ 156 assignable to C(3) were observed in their ^{13}C NMR spectra. The ^{1}H NMR spectra were good agreement with their structures.



4a R = Me
4c R = allyl
4d R = Bn

5a R = Me, R'X = BnBr 50%
5c R = allyl, R'X = MeI 49%
5d R = Bn, R'X = MeI 50%

Scheme 3

Compound (**2**) was treated with two equivalents of sodium hydride in DMF at 0 ˚C, and subsequent addition of two equivalents of alkyl halides to achieve simultaneous 2,*S*-dialkylation provided 2-alkyl-3-(alkylsulfanyl)-2*H*-1,4-benzothiazines (**6**) directly in moderate yields, as shown in Scheme 4.



2

6a RX = MeI 52%
6b RX = CH_2=$CHCH_2$Br 65%
6c RX = BnBr 61%

Scheme 4



2

7a n = 2 48%
7b n = 3 62%
7c n = 4 43%

Scheme 5

Compound **2** was then subjected to the treatment with two equivalents of sodium hydride in DMF at 0 ˚C, and an equimolar amount of 1,ω-dibromoalkanes in place of two equivalents of alkyl halides were added. Surprisingly, however, it was found that the products obtained were 4,*S*-dialkylated tricyclic compounds (**7**), as depicted in Scheme 5. The production of these compounds is presumably due to the avoidance of the structural strain of the 2,*S*-dilakylated products. Synthesis and biological activities of

thiazolo[2,3-*c*][1,4]benzothiazine derivatives (n = 2) have been reported.[10]



4h **8** 69%

Scheme 6

The preparation of a 9*H*-thieno[3,2-*b*][1,4]benzothiazine derivative was also achieved. When compound (**4h**) was treated with two equivalents of sodium hydride in DMF at 0 ˚C, immediate cyclization occurred to give 3-amino-9*H*-thieno[3,2-*b*][1,4]benzothiazine-2-carbonitrile (**8**) in relatively good yield, as illustrated in Scheme 6. Some compounds with 9*H*-thieno[3,2-*b*][1,4]benzothiazine structure have been prepared and reported to exhibit biological activities.[11]

In conclusion, we have demonstrated that 4*H*- and 2*H*-1,4-benzothiazine derivatives carrying an alkylsulfanyl substituent at the 3-position can be produced *via* easily operated reaction sequences starting from 2-[(cyanomethyl)sulfanyl]phenyl isothiocyanate, which is readily prepared from a commercially available starting material, 2-aminobenzenthiol. The present methods proved to be applicable to the construction of some 1,4-benzothiazine-based tricyclic heterocyclic compounds.

EXPERIMENTAL

All melting points were obtained on a Laboratory Devices MEL-TEMP II melting apparatus and are uncorrected. IR spectra were recorded with a Perkin–Elmer Spectrum 65 FTIR spectrophotometer. ^{1}H NMR and ^{13}C NMR spectra were recorded using TMS as an internal reference with a JEOL ECP500 FT NMR spectrometer operating at 500 and 125 MHz, respectively. High-resolution MS spectra were measured by a JEOL JMS-T100GCV (EI, TOF; 70 eV) or a Thermo Scientific Exactive (DART or ESI, positive) spectrometer. Elemental analyses were performed with an Elementar Vario EL II instrument. TLC was carried out on Merck Kieselgel 60 PF_{254}. Column chromatography was performed using WAKO GEL C-200E. All of the organic solvents used in this study were dried over appropriate drying agents and distilled prior to use.

Starting Materials. 2-[(2-Isocyanophenyl)sulfanyl]acetonitrile (**1**) was prepared according to the reported method.[8] Butyllithium was supplied by Asia Lithium Corporation. All other chemicals used in this study were commercially available.

2-[(2-Isothiocyanatophenyl)sulfanyl]acetonitrile (2). This compound was prepared by a slight modification of Fujiwara's method.[9] A mixture of **1** (0.93 g, 5.3 mmol), S_8 (0.17 g, 5.3 mmol), Se (25 mg,

0.32 mmol), and Et_3N (1.3 g, 13 mmol) in THF (5 mL) was stirred at rt for 1 h. The precipitate was filtered off through a Celite 545 pad under reduced pressure and filtrate was concentrated by evaporation. The residue was purified by column chromatography on SiO_2 to give **2** (0.94 g, 85%); a yellow oil; R_f 0.32 (CH_2Cl_2/hexane 1:1); IR (neat) 2249, 2064 cm^{-1}; ^1H NMR ($CDCl_3$) δ 3.63 (s, 2H), 7.326 (t, J = 7.4 Hz, 1H), 7.333 (d, J = 7.4 Hz, 1H), 7.40 (td, J = 7.4, 1.7 Hz, 1H), 7.64 (dd, J = 7.4, 1.7 Hz, 1H); ^{13}C NMR ($CDCl_3$) δ 20.4, 115.6, 127.1, 128.0, 128.8, 130.6, 134.2, 134.6 (2 overlapped Cs). HR-MS (EI). Calcd for $C_9H_6N_2S_2$ (M): 205.9972. Found: *m*/*z* 205.9960.

3-Thioxo-3,4-dihydro-2*H*-1,4-benzothiazine-2-carbonitrile (3). To a stirred suspension of NaH (60% in mineral oil; 40 mg, 1.0 mmol) in DMF (2 mL) at 0 °C was added a solution of **2** (0.21 g, 1.0 mmol) in DMF (2 mL) dropwise. After 10 min, saturated aqueous NH_4Cl (15 mL) was added and the mixture was extracted with AcOEt (3 × 10 mL). The combined extracts were washed with H_2O (3 × 15 mL) and brine (10 mL), dried (Na_2SO_4), and concentrated by evaporation. The residual solid was recrystallized from hexane/CH_2Cl_2 to give **3** (0.13 g, 65%); an orange solid; mp 114–116 °C; IR (KBr) 3208, 2242, 1601, 1542, 1478, 1443, 1390, 1104, 1067 cm^{-1}; ^1H NMR (DMSO-d_6) δ 5.91 (s, 1H), 7.26 (t, J = 7.6 Hz, 1H), 7.36 (d, J = 7.6 Hz, 1H), 7.41 (t, J = 7.6 Hz, 1H), 7.57 (d, J = 7.6 Hz, 1H), 13.28 (br s, 1H); ^{13}C NMR (DMSO-d_6) δ 37.03, 115.31, 117.73, 118.53, 125.71, 128.49, 128.60, 135.67, 182.15. HR-MS (EI). Calcd for $C_9H_6N_2S_2$ (M): 205.9972. Found: *m*/*z* 205.9970. Anal. Calcd for $C_9H_6N_2S_2$: C, 52.40; H, 2.93; N, 13.58. Found: C, 52.17; H, 3.12; N, 13.30.

Typical Procedure for the Preparation of 2-(Alkylsulfanyl)-4*H*-1,4-benzothiazines (4). 3-(Methylsulfanyl)-4*H*-1,4-benzothiazine-2-carbonitrile (4a). After compound **2** (0.21 g, 1.0 mmol) was treated with NaH as described above, MeI (0.14 g, 1.0 mmol) was added dropwise. After 10 min, the mixture was worked up as described for the preparation of **3**. The residual solid was recrystallized from hexane/CH_2Cl_2 to give **4a** (0.15 g, 68%); a yellow solid; mp 153–155 °C; IR (KBr) 3332, 2174, 1542, 1469 cm^{-1}; ^1H NMR (DMSO-d_6) δ 2.55 (s, 3H), 6.96 (d, J = 7.6 Hz, 1H), 7.05–7.10 (m, 2H), 7.19 (t, J = 7.3 Hz, 1H), 10.01 (s, 1H); ^{13}C NMR (DMSO-d_6) δ 16.22, 65.59, 116.60, 117.20, 118.29, 126.13, 126.89, 128.41, 139.54, 155.86. HR-MS (EI). Calcd for $C_{10}H_8N_2S_2$ (M): 220.0129. Found: *m*/*z* 220.0130. Anal. Calcd for $C_{10}H_8N_2S_2$: C, 54.52; H, 3.66; N, 12.72. Found: C, 54.31; H, 3.70; N, 12.59.

3-(Butylsulfanyl)-4*H*-1,4-benzothiazine-2-carbonitrile (4b): a yellow solid; mp 69–71 °C (hexane/CH_2Cl_2); IR (KBr) 3278, 2190, 1550, 1463 cm^{-1}; ^1H NMR ($CDCl_3$) δ 0.93 (t, J = 7.4 Hz, 3H), 1.42–1.49 (m, 2H), 1.63–1.69 (m, 2H), 2.99 (t, J = 7.4 Hz, 2H), 6.57 (br s, 1H), 6.63 (dd, J = 8.0, 1.1 Hz, 1H), 6.99 (dd, J = 7.4, 1.7 Hz, 1H), 7.03 (ddd, J = 8.0, 7.4, 1.1 Hz, 1H), 7.10 (td, J = 7.4, 1.7 Hz, 1H); ^{13}C NMR ($CDCl_3$) δ 13.50, 21.56, 31.64, 34.51, 73.38, 115.62, 116.68, 119.18, 126.30, 127.32, 128.14, 139.23, 152.98. HR-MS (EI). Calcd for $C_{13}H_{14}N_2S_2$ (M): 262.0598. Found: *m*/*z* 262.0595.

3-[(Prop-2-enyl)sulfanyl]-4*H*-1,4-benzothiazine-2-carbonitrile (4c): a yellow solid; mp 151–153 °C (hexane/THF); IR (KBr) 3321, 2183, 1635, 1541, 1463 cm^{-1}; ^1H NMR ($CDCl_3$) δ 3.58 (d, *J* = 6.9 Hz, 2H), 5.22–5.27 (m, 2H), 5.89–5.97 (m, 1H), 6.59 (d, *J* = 7.4 Hz, 1H), 6.64 (s, 1H), 6.97 (d, *J* = 7.4 Hz, 1H), 7.03 (t, *J* = 7.4 Hz, 1H), 7.09 (t, *J* = 7.4 Hz, 1H); ^{13}C NMR ($CDCl_3$) δ 37.69, 74.63, 115.52, 116.62, 118.83, 119.72, 126.32, 127.34, 128.14, 132.68, 139.09, 151.55. HR-MS (EI). Calcd for $C_{12}H_{10}N_2S_2$ (M): 246.0285. Found: *m*/*z* 246.0280. Anal. Calcd for $C_{12}H_{10}N_2S_2$: C, 58.51; H, 4.09; N, 11.37. Found: C, 58.32; H, 4.05; N, 11.52.

3-[(Phenylmethyl)sulfanyl]-4*H*-1,4-benzothiazine-2-carbonitrile (4d): a yellow solid; mp 100–103 °C (hexane/CH_2Cl_2); IR (KBr) 3258, 2191, 1550, 1466 cm^{-1}; ^1H NMR (DMSO-d_6) δ 4.30 (s, 2H), 6.97 (t, *J* = 6.9 Hz, 2H), 7.02 (t, *J* = 6.9 Hz, 1H), 7.15–7.27 (m, 6H), 10.01 (br s, 1H); ^{13}C NMR (DMSO-d_6) δ 36.93, 69.05, 116.42, 116.86, 117.66, 125.97, 126.79, 127.44, 128.33, 128.45, 128.72, 136.38, 139.45, 152.21. HR-MS (EI). Calcd for $C_{16}H_{12}N_2S_2$ (M): 296.0442. Found: *m*/*z* 296.0439. Anal. Calcd for $C_{16}H_{12}N_2S_2$: C, 64.83; H, 4.08; N, 9.45. Found: C, 64.82; H, 4.13; N, 9.36.

3-[(2-Oxo-2-phenylethyl)sulfanyl]-4*H*-1,4-benzothiazine-2-carbonitrile (4e): a yellow solid; mp 150–153 °C (hexane/CH_2Cl_2); IR (KBr) 3328, 2172, 1682 cm^{-1}; ^1H NMR ($CDCl_3$) δ 4.26 (s, 2H), 6.65 (dd, *J* = 7.4, 1.1 Hz, 1H), 6.93 (d, *J* = 7.4 Hz, 1H), 7.00 (td, *J* = 7.4, 1.1 Hz, 1H), 7.06 (td, *J* = 7.4 Hz, 1.1 Hz, 1H), 7.54 (t, *J* = 7.4 Hz, 2H), 7.68 (tt, *J* = 7.4, 1.1 Hz, 1H), 7.98 (dd, *J* = 7.4, 1.1 Hz, 2H), 8.49 (br s, 1H); ^{13}C NMR ($CDCl_3$) δ 39.32, 73.11, 115.96, 116.47, 118.27, 126.24, 127.17, 128.21, 128.83, 129.18, 134.75, 134.92, 139.23, 150.30, 196.96. HR-MS (EI). Calcd for $C_{17}H_{12}N_2OS_2$ (M): 324.0391. Found: *m*/*z* 324.0376. Anal. Calcd for $C_{17}H_{12}N_2OS_2$: C, 62.94; H, 3.73; N, 8.63. Found: C, 62.81; H, 3.60; N, 8.61.

3-{[2-(4-Chlorophenyl)-2-oxoethyl]sulfanyl}-4*H*-1,4-benzothiazine-2-carbonitrile (4f): a yellow solid; mp 154–156 °C (hexane/CH_2Cl_2); IR (KBr) 3337, 2173, 1678 cm^{-1}; ^1H NMR (DMSO-d_6) δ 4.73 (s, 2H), 6.83 (d, *J* = 8.0 Hz, 1H), 6.99 (dd, *J* = 8.0, 1.7 Hz, 1H), 7.03 (ddd, *J* = 8.0, 7.4, 1.7 Hz, 1H), 7.12 (ddd, *J* = 8.0, 7.4, 1.1 Hz, 1H), 7.57 (d, *J* = 8.6 Hz, 2H), 7.93 (d, *J* = 8.6 Hz, 2H), 10.02 (br s, 1H); ^{13}C NMR (DMSO-d_6) δ 39.50, 79.12, 116.48, 116.65, 118.69, 125.98, 126.73, 128.32, 128.87, 130.31, 133.66, 138.69, 139.48, 151.80, 192.39. HR-MS (ESI). Calcd for $C_{17}H_{12}ClN_2OS_2$ (M+H): 359.0079. Found: *m*/*z* 359.0066. Anal. Calcd for $C_{17}H_{11}ClN_2OS_2$: C, 56.90; H, 3.09; N, 7.81. Found: C, 56.71; H, 3.24; N, 7.75.

1,1-Dimethylethyl 2-[(2-Cyano-4*H*-1,4-benzothiazin-2-yl)sulfanyl]acetate (4g): a yellow viscous oil; R_f 0.34 (AcOEt/hexane 1:3); IR (neat) 3281, 2193, 1727 cm^{-1}; ^1H NMR ($CDCl_3$) δ 1.54 (s, 9H), 3.43 (s, 2H), 6.64 (d, *J* = 7.4 Hz, 1H), 6.95 (d, *J* = 7.4 Hz, 1H), 7.01 (t, *J* = 7.4 Hz, 1H), 7.06 (t, *J* = 7.4Hz, 1H), 8.93 (br s, 1H); ^{13}C NMR ($CDCl_3$) δ 27.86, 36.47, 71.80, 84.61, 115.87, 116.48, 118.55, 126.20, 127.22, 128.14, 139.31, 150.68, 171.57. HR-MS (ESI). Calcd for $C_{15}H_{16}N_2O_2S_2$ (M+H): 321.0731. Found: *m*/*z* 321.0725.

3-[(Cyanomethyl)sulfanyl]-4*H*-1,4-benzothiazine-2-carbonitrile (4h): a brown viscous oil; R_f 0.40 (AcOEt/hexane 1:4); IR (neat) 3288, 2194 cm^{-1}; ^1H NMR ($CDCl_3$) δ 3.69 (s, 2H), 6.71 (d, *J* = 8.0 Hz, 1H), 6.937 (br s, 1H), 6.944 (d, *J* = 7.4 Hz, 1H), 7.06 (t, *J* = 7.4 Hz, 1H), 7.11 (dd, *J* = 8.0, 7.4 Hz, 1H); ^{13}C NMR ($CDCl_3$) δ 19.98, 78.91, 115.56, 115.79, 116.30, 118.02, 127.05, 127.38, 128.62, 138.79, 146.66. HR-MS (EI). Calcd for $C_{11}H_7N_3S_2$ (M): 245.0081. Found: *m*/*z* 245.0073.

Typical Procedure for the Preparation of 2-Alkyl-3-(alkylsulfanyl)-2*H*-1,4-benzothiazine-2-carbonitriles (5). 2-Methyl-3-[(phenylmethyl)sulfanyl]-2*H*-1,4-benzothiazine-2-carbonitrile (5d). To a stirred suspension of NaH (60% in mineral oil; 22 mg, 0.55 mmol) in DMF (2 mL) at 0 ˚C was added a solution of **4d** (0.16 g, 0.55 mmol) in DMF (2 mL) dropwise. Evolution of H_2 gas had ceased, MeI (78 mg, 0.55 mmol) was added. After 15 min, the mixture was worked up as described for the preparation of **3**. The residue was purified by column chromatography on SiO_2 (AcOEt/hexane 1:7) to give **5d** (85 mg, 50%); a white solid; mp 151–153 ˚C (hexane); IR (KBr) 2231, 1594 cm^{-1}; ^1H NMR ($CDCl_3$) δ 1.80 (s, 3H), 4.34 (s, 2H), 7.10 (t, *J* = 7.4 Hz, 1H), 7.18–7.29 (m, 5H), 7.33 (d, *J* = 7.4 Hz, 2H), 7.38 (d, *J* = 7.4 Hz, 1H); ^{13}C NMR ($CDCl_3$) δ 21.61, 35.58, 36.66, 117.39, 118.73, 126.76, 126.85, 127.26, 127.64, 128.07, 128.68, 129.24, 135.92, 141.28, 156.18. HR-MS (EI). Calcd for $C_{17}H_{14}N_2S_2$ (M): 310.0598. Found: *m*/*z* 310.0607. Anal. Calcd for $C_{17}H_{14}N_2S_2$: C, 65.77; H, 4.55; N, 9.02; S, 20.66. Found: C, 65.48; H, 4.49; N, 9.05; S, 20.56.

3-(Methylsulfanyl)-2-(phenylmethyl)-2*H*-1,4-benzothiazine-2-carbonitrile (5a): a white solid; mp 118–120 ˚C (hexane/CH_2Cl_2); IR (KBr) 2227, 1593 cm^{-1}; ^1H NMR ($CDCl_3$) δ 2.52 (s, 3H), 2.93 (d, *J* = 13.7 Hz, 1H), 3.22 (d, *J* = 13.7 Hz, 1H), 7.20–7.21 (m, 3H), 7.30–7.35 (m, 5H), 7.46 (d, *J* = 7.4 Hz, 1H); ^{13}C NMR ($CDCl_3$) δ 14.24, 39.15, 44.23, 116.24, 117.62, 126.63, 126.78, 127.36, 128.05, 128.20, 128.35, 130.45, 132.43, 141.25, 156.58. HR-MS (EI). Calcd for $C_{17}H_{14}N_2S_2$ (M): 310.0598. Found: *m*/*z* 310.0589. Anal. Calcd for $C_{17}H_{14}N_2S_2$: C, 65.77; H, 4.55; N, 9.02. Found: C, 65.53; H, 4.51; N, 9.01.

2-Methyl-3-[(prop-2-enyl)sulfanyl]-2*H*-1,4-benzothiazine-2-carbonitrile (5c): a pale-yellow oil; R_f 0.54 (AcOEt/hexane 1:10); IR (neat) 2232, 1661, 1637, 1594 cm^{-1}; ^1H NMR ($CDCl_3$) δ 1.88 (s, 3H), 3.84 (d, *J* = 6.9 Hz, 2H), 5.20 (d, *J* = 10.3 Hz, 1H), 5.35 (d, *J* = 16.6 Hz, 1H), 5.88–5.99 (m, 1H), 7.16 (t, *J* = 7.4 Hz, 1H), 7.28–7.31 (m, 2H), 7.40 (d, *J* = 8.0 Hz, 1H); ^{13}C NMR ($CDCl_3$) δ 21.6, 33.8, 36.7, 117.4, 118.6, 119.1, 126.7, 126.8, 127.2, 128.0, 131.9, 141.2, 155.8. HR-MS (DART). Calcd for $C_{13}H_{13}N_2S_2$ (M+H): 261.0520. Found: *m*/*z* 261.0508.

Typical Procedure for the Preparation of 2-Alkyl-3-(alkylsulfanyl)-2*H*-1,4-benzothiazine-2-carbonitriles (6). 2-Methyl-3-(methylsulfanyl)-2*H*-1,4-benzothiazine-2-carbonitrile (6a). To a stirred suspension of NaH (60% in mineral oil; 53 mg, 1.3 mmol) in DMF (2 mL) at 0 ˚C was added a solution of **2** (0.15 g, 0.66 mmol) in DMF (2 mL) dropwise. Evolution of H_2 gas had ceased, MeI (0.19 g, 1.3 mmol) was added. After 15 min, the mixture was worked up as described for the preparation of **3**. The

residue was purified by column chromatography on SiO_2 to give **6a** (81 mg, 52%); a pale-yellow oil; R_f 0.56 (AcOEt/hexane 1:7); IR (neat) 2230, 1592 cm^{-1}; ^1H NMR ($CDCl_3$) δ 1.89 (s, 3H), 2.56 (s, 3H), 7.16 (ddd, *J* = 8.0, 7.4, 1.1 Hz, 1H), 7.29–7.32 (m, 2H), 7.42 (dd, *J* = 8.0, 1.1 Hz, 1H); ^{13}C NMR ($CDCl_3$) δ 13.98, 21.69, 36.71, 117.51, 118.50, 126.61, 126.81, 127.20, 128.02, 141.38, 157.18. HR-MS (EI). Calcd for $C_{11}H_{10}N_2S_2$ (M): 234.0285. Found: *m*/*z* 234.0274. Anal. Calcd for $C_{11}H_{10}N_2S_2$: C, 56.38; H, 4.30; N, 11.95; S, 27.37. Found: C, 56.51; H, 4.65; N, 11.83; S, 27.55.

2-(Prop-2-enyl)-3-[(prop-2-enyl)sulfanyl]-2*H*-1,4-benzothiazine-2-carbonitrile (6b): a pale-yellow oil; R_f 0.70 (AcOEt/hexane 1:3); IR (neat) 2239, 1639, 1593 cm^{-1}; ^1H NMR ($CDCl_3$) δ 2.53 (dd, *J* = 13.5, 7.4 Hz, 1H), 2.81 (dd, *J* = 13.5, 6.9 Hz, 1H), 3.81–3.90 (m, 2H), 5.19–5.23 (m, 2H), 5.31–5.37 (m, 2H), 5.85–5.98 (m, 2H), 7.16 (t, *J* = 7.4 Hz, 1H), 7.26–7.31 (m, 2H), 7.38 (d, *J* = 8.0 Hz, 1H); ^{13}C NMR ($CDCl_3$) δ 33.98, 37.97, 42.51, 116.12, 117.67, 119.09, 122.05, 126.68, 126.78, 127.34, 127.98, 129.16, 131.88, 141.13, 154.91. HR-MS (EI). Calcd for $C_{15}H_{14}N_2S_2$ (M): 286.0598. Found: *m*/*z* 286.0580.

2-(Phenylmethyl)-3-[(phenylmethyl)sulfanyl]-2*H*-1,4-benzothiazine-2-carbonitrile (6c): a pale-yellow solid; mp 100–102 °C (hexane); IR (KBr) 2241, 1596 cm^{-1}; ^1H NMR ($CDCl_3$) δ 2.93 (d, *J* = 13.2 Hz, 1H), 3.20 (d, *J* = 13.2 Hz, 1H), 4.33 (d, *J* =13.7 Hz, 1H), 4.43 (d, *J* = 13.7 Hz, 1H), 7.14 (d, *J* = 6.9 Hz, 2H), 7.20 (t, *J* = 7.4 Hz, 1H), 7.24–7.37 (m, 10H), 7.48 (d, *J* = 7.4 Hz, 1H); ^{13}C NMR ($CDCl_3$) δ 35.7, 39.3, 44.1, 116.1, 117.9, 126.6, 126.9, 127.4, 127.5, 128.1, 128.2, 128.4, 128.6, 129.3, 130.5, 132.3, 136.0, 141.2, 155.5. Anal. Calcd for $C_{23}H_{18}N_2S_2$: C, 71.47; H, 4.69; N, 7.25; S, 16.59. Found: C, 71.13; H, 4.80; N, 7.22; S, 16.72.

Typical Procedure for the Preparation of Tricyclic Benzothiazine-Fused Compounds (7). 1,2-Dihydrothiazolo[2,3-*c*][1,4]benzothiazine-4-carbonitrile (7a). To a stirred suspension of NaH (60% in mineral oil; 79 mg, 2.0 mmol) in DMF (2 mL) at 0 °C was added a solution of **2** (0.20 g, 0.99 mmol) in DMF (2 mL) dropwise. Evolution of H_2 gas had ceased, $Br(CH_2)_2Br$ (0.19 g, 0.99 mmol) was added. After 2.5 h, the mixture was worked up as described for the preparation of **3**. The residue was purified by column chromatography on SiO_2 (AcOEt/hexane 1:2) to give **7a** (81 mg, 48%); a yellow solid; mp 137–139 °C (hexane/CH_2Cl_2); IR (KBr) 2184, 1550 cm^{-1}; ^1H NMR ($CDCl_3$) δ 3.46 (t, *J* = 6.9 Hz, 2H), 3.95 (t, *J* = 6.9 Hz, 2H), 6.65 (d, *J* = 8.0 Hz, 1H), 6.97–6.99 (m, 2H), 7.08–7.12 (m, 1H); ^{13}C NMR ($CDCl_3$) δ 29.2, 53.0, 64.8, 113.2, 116.8, 119.1, 125.6, 127.2, 128.1, 140.4, 157.2. Anal. Calcd for $C_{11}H_8N_2S_2$: C, 56.87; H, 3.47; N, 12.06; S, 27.60. Found: C, 56.58; H, 3.37; N, 12.25; S, 27.87.

2,3-Dihydro-1*H*-[1,4]benzothiazino[3,4-*b*]thiazine-5-carbonitrile (7b): a yellow solid; mp 117–119 °C (hexane/CH_2Cl_2); IR (KBr) 2185, 1534 cm^{-1}; ^1H NMR ($CDCl_3$) δ 2.34–2.40 (m, 2H), 3.03 (t, *J* = 7.4 Hz, 2H), 4.00 (t, *J* = 6.3 Hz, 2H), 6.87 (d, *J* = 8.0 Hz, 1H), 7.08–7.12 (m, 2H), 7.19–7.24 (m, 1H); ^{13}C NMR ($CDCl_3$) δ 24.0, 26.9, 45.9, 70.8, 114.4, 116.8, 122.9, 125.9, 128.06, 128.10, 142.7, 158.0. Anal. Calcd for

$C_{12}H_{10}N_2S_2$: C, 58.51; H, 4.09; N, 11.37; S, 26.03. Found: C, 58.24; H, 4.22; N, 11.41; S, 26.20.

8,9,10,11-Tetrahydro[1,4]benzothiazino[3,4-*b*]thiazepine-6-carbonitrile (7c): a yellow solid; mp 135–137 °C (hexane/CH_2Cl_2); IR (KBr) 2187, 1527 cm^{-1}; ^1H NMR ($CDCl_3$) δ 1.94–1.97 (m, 4H), 2.72–2.75 (m, 2H), 4.06–4.10 (m, 2H), 6.90 (d, *J* = 8.0 Hz, 1H), 6.93 (dd, *J* = 7.4, 1.7 Hz, 1H), 7.00 (t, *J* = 7.4 Hz, 1H), 7.09 (ddd, *J* = 8.0, 7.4, 1.7 Hz, 1H); ^{13}C NMR ($CDCl_3$) δ 28.5, 29.1, 34.3, 52.0, 71.0, 115.2, 117.6, 123.3, 126.2, 127.6, 127.9, 142.9, 157.7. Anal. Calcd for $C_{13}H_{12}N_2S_2$: C, 59.97; H, 4.65; N, 10.76; S, 24.63. Found: C, 59.73; H, 4.72; N, 10.80; S, 24.93.

3-Amino-9*H*-thieno[3,2-*b*][1,4]benzothiazine-2-carbonitrile (8). To a stirred suspension of NaH (60% in mineral oil; 88 mg, 2.2 mmol) in DMF (7 mL) at 0 °C was added a solution of **4g** (0.28 g, 1.1 mmol) in DMF (3 mL) dropwise. After 20 min, the mixture was worked up as described for the preparation of **3**. The residual solid was purified by recrystallization from hexane/$CHCl_3$ to give **8** (0.19 g, 69%); a brown solid; mp 181–184 °C; IR (KBr) 3457, 3368, 3269, 2187, 1619 cm^{-1}; ^1H NMR (DMSO-d_6) δ 6.21 (s, 2H), 6.57 (d, *J* = 7.4 Hz, 1H), 6.83 (td, *J* = 7.4, 1.1 Hz, 1H), 6.90 (d, *J* = 8.0 Hz, 1H), 7.00 (ddd, *J* = 8.0, 7.4, 1.1 Hz, 1H), 9.90 (s, 1H); ^{13}C NMR (500 MHz, $CDCl_3$) δ 64.10, 93.96, 115.22 (2 overlapped Cs), 116.48, 123.68, 127.10, 127.98, 140.38, 145.05, 151.94. HR-MS (EI). Calcd for $C_{11}H_7N_3S_2$ (M): 245.0081. Found: *m*/*z* 245.0088. Anal. Calcd for $C_{11}H_7N_3S_2$: C, 53.85; H, 2.88; N, 17.13. Found: C, 53.70; H, 3.16; N, 16.75.

ACKNOWLEDGEMENTS

We thank Mrs. Miyuki Tanmatsu of this university for recording mass spectra and performing combustion analyses.

REFERENCES AND NOTES

1. (a) S. C. Schou, H. C. Hansen, T. M. Tagmose, H. C. M. Boonen, A. Worsaae, M. Drabowski, P. Wahl, P. O. G. Arkhammar, T. Bodvarsdotir, M. H. Antonie, P. Lebrun, and J. B. Hansen, *Bioorg. Med. Chem.*, 2005, **13**, 141; (b) B. S. Rathore and M. Kumar, *Bioorg. Med. Chem.*, 2006, **14**, 5678; (c) R. Dixit, Y. Dixit, N. Gautam, and D. C. Gautam, *Indian J. Heterocycl. Chem.*, 2007, **16**, 391; (d) N. Gautam, M. Sharma, V. Gautam, and D. C. Gautam, *Asian J. Chem.*, 2010, **22**, 5380; (e) G. S. Kalwanja, S. Chomal, and S. Choudhary, *Asian J. Chem.*, 2011, **23**, 5133; (f) N. Gautam, A. K. Bishnol, A. Guleria, D. K. Jangid, S. K. Gupta, and D. C. Gautam, *Heterocycl. Commun.*, 2013, **19**, 37; (g) N. Gautam, Y. Dixit, R. Dixit, S. K. Gupta, and D. C. Gautam, *Phosphorus, Sulfur Silicon Relat. Elem.*, 2013, **188**, 1127; (h) B. J. Khairnar, P. S. Girase, and B. R. Chaudhari, *J. Chem. Pharm. Res.*, 2015, **7**, 561; (i) S. Preet and D. S. Cannco, *RSC Adv.*, 2015, **5**, 79232; (j) P. K. Sharma and R. M. S. Singh, *Pharm. Chem.*, 2016, **8**, 156; (k) P. K. Sharma and P. Singh, *Pharm. Chem.*, 2016, **8**,

191.

2. (a) X.-S. He, *U.S.* US 6100255 A (*Chem. Abstr.*, 2000, **133**, 150581); (b) S. Mor, P. Pahal, and B. Narashimhan, *Eur. J. Med. Chem.*, 2012, **53**, 176; (c) A. Mancini, A. Chelini, A. Di Capua, L. Castelli, S. Brogi, M. Paolino, G. Giuliani, A. Cappelli, M. Frosini, J. Magistretti, and M. Anzini, *Eur. J. Med. Chem.*, 2017, **126**, 614.
3. T. Stalling, K. Johannes, S. Polina, and J. Martens, *J. Heterocycl. Chem.*, 2013, **50**, 654.
4. S. Pippich and H. Bartsch, *Heterocycles*, 1996, **43**, 1967.
5. (a) W. Zhong, X. Sun, and W, Su, *Heteroat. Chem.*, 2008, **19**, 332; (b) X. Yang and L. Liqiang, *Phosphorus, Sulfur Silicon Relat. Elem.*, 2013, **188**, 1327; (c) L. Leone, O. Crescenzi, R. Amorati, L. Valgimigli, A. Napolitano, V. Barone, and M. d'Iachia, *Org. Lett.*, 2013, **15**, 4944.
6. (a) O. A. Attanasi, P. Filippone, S. Lillini, F. Mantallini, S. Nicolini, J. M. de los Santos, R. Ignacio, D. Apsricio, and F. Palacios, *Tetrahedron*, 2008, **64**, 9264; (b) M. Franz, T. Stalling, R. Schaper, M. Schmidtmann, and J. Martens, *Synthesis*, 2017, **49**, 4045.
7. Syntheses of 2,3-dihydro-4*H*-1,4-benzothiazine-3-thiones: (a) M. Takahashi and M. Ohba, *Heterocycles*, 1995, **41**, 2263; (b) R. S. Varma and D. Kumar, *Org. Lett.*, 1999, **1**, 697; (c) S. S. Rao, K. S. Chowdary, A. Prashant, and V. S. H. Krishnan, *Synth. Commun.*, 2001, **31**, 3469.
8. K. Kobayashi, K. Hayashi, D. Iitsuka, O. Morikawa, and H. Konishi, *Synthesis*, 2006, 1077.
9. S. Fujiwara, T. Shin-Ike, N. Sonoda, M. Aoki, K. Okada, N. Miyoshi, and N. Kambe, *Tetrahedron Lett.*, 1991, **32**, 3503.
10. N. Suzuki, A. Nakayama, T. Saijo, M. Hasegawa, and S. Yokohama, *Jpn. Kokai Tokkyo Koho*, 1992, JP 04273883 (*Chem. Abstr.*, 1993, **118**, 191728).
11. (a) L. Nagarapu and N. Ravirala, *Heterocycl. Commun.*, 2001, **7**, 433; (b) A. Barazarte, J. Camacho, J. Domínguez, G. Lobo, N. Gamboa, J. Rodorigues, M. V. Capparelli, A. Alvarez-Larena, S. Andujar, D. Enriz, and J. Charris, *Bioorg. Med. Chem.*, 2008, **16**, 3661; (c) M. O. Taha, A. M. Qandil, T. Al-Haraznah, R. Abu Khalaf, H. Zalloum, and A. G. Al-Bakri, *Chem. Biol. Drug Des.*, 2011, **78**, 391.